Your browser doesn't support javascript.
loading
IL-22, a vital cytokine in autoimmune diseases.
Li, Jiajin; Wu, Zhen; Wu, Yuxin; Hu, Xin Yu; Yang, Jun; Zhu, Dacheng; Wu, Mingyue; Li, Xin; Bentum-Ennin, Lutterodt; Hu, Wanglai.
Afiliación
  • Li J; The second Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Wu Z; The First Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Wu Y; The First Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Hu XY; The second Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Yang J; The second Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Zhu D; The First Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Wu M; The School of pharmacy, Anhui Medical University, Hefei, China.
  • Li X; The First Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • Bentum-Ennin L; The School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
  • Hu W; The School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Clin Exp Immunol ; 2024 Apr 23.
Article en En | MEDLINE | ID: mdl-38651179
ABSTRACT
Interleukin-22 (IL-22) is a vital cytokine that is dysregulated in various autoimmune conditions including rheumatoid arthritis (RA), multiple sclerosis (MS), and Alzheimer's disease (AD). As the starting point for the activation of numerous signaling pathways, IL-22 plays an important role in the initiation and development of autoimmune diseases. Specifically, imbalances in IL-22 signaling can interfere with other signaling pathways, causing cross regulation of target genes which ultimately leads to the development of immune disorders. This review delineates the various connections between the IL-22 signaling pathway and autoimmune disease, focusing on the latest understanding of the cellular sources of IL-22 and its effects on various cell types. We further explore progress with pharmacological interventions related to targeting IL-22, describing how such therapeutic strategies promise to usher in a new era in the treatment of autoimmune disease.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Clin Exp Immunol Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Clin Exp Immunol Año: 2024 Tipo del documento: Article País de afiliación: China